Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug Resistance

NCT04150068 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04150068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug Resistance
Lead sponsor
Gilead Sciences
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
November 21, 2019
Completion date
January 31, 2028
Enrollment
72 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection